10th January 2019

The Migraine Trust is very disappointed at NICE decision

NICE has decided not to recommend erenumab for preventing migraine

The Migraine Trust is very disappointed about the National Institute for Health and Care Excellence’s (NICE) decision not to recommend erenumab (Aimovig) for preventing migraine.

Produced by Novartis, the European Medicines Agency granted a licence for its use in the prevention of migraine in adults who experience at least four migraine days per month last July.

NICE has today (10 January) published draft guidance for public consultation (it will only take a few minutes to register online with NICE and then you can submit your comments in the blue box at the bottom of the page), which The Migraine Trust is encouraging people in the UK with migraine to respond to.

Commenting on the announcement, Wendy Thomas, Chief Executive of The Migraine Trust, said:

“This is extremely disappointing, and devastating for people whose lives are blighted by migraine.

“It is terrible that people with migraine have had to wait so long for their own treatment, the first medication dedicated to treating migraine.

“Now, after proving effective to many, it is not accessible to those who can’t afford to purchase it privately.”